Biblio Discovery — Demo Discovery Service

3 hasil untuk "Subhashis Banerjee"

Menampilkan 1–3 · 0,59 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II , Randomized, Double‐Blind , Placebo‐Controlled Trial

    Eric Francis Morand; Marilyn C. Pike; Joan T. Merrill dkk.

    Arthritis & Rheumatology · 2022 · Inggris · OpenAlex Scopus

    OBJECTIVE: To assess the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in a phase II trial in adult patients with active systemic lupus erythematosus (SLE). METHODS: Adults with active SLE were enrolled from 162 sites in 17 countries. Patients (n = 363)…

  2. Artikel Jurnal

    Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

    April Wang Armstrong; Melinda Gooderham; Richard Bruce Warren dkk.

    Journal of the American Academy of Dermatology · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: Effective, well-tolerated oral psoriasis treatments are needed. OBJECTIVE: To compare the efficacy and safety of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, versus placebo and apremilast in adults with moderate to severe plaque psoriasis. METHODS…

  3. Artikel Jurnal Teks lengkap

    Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

    Bruce E Strober; Diamant Thaçi; Howard L. Sofen dkk.

    Journal of the American Academy of Dermatology · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, inhibits cytokine signaling in psoriasis pathogenesis. OBJECTIVE: The objective of this study was to demonstrate deucravacitinib superiority versus placebo and apremilast in moderate to severe plaque psoriasis…